OLEMA PHARMACEUTICALS INC

OLMANASDAQ

🏆 #1864 by market capEarnings Nov 9US Equity

$716.09▲ $42.68 (+5.96%)

Simulated price

1h—

24h▲ 6.0%

7d—

14d—

30d—

1y—

🏦Market Cap

$1.04B

Small Cap

📈Revenue Growth (YoY)

—

📊Gross Margin

—

💵FCF Margin

—

⚖️P/S Ratio

—

Otter Score

Fair

No chart data available for OLMA.

Trading Snapshot

Day Range: $704.95 – $729.21
52-Week Range: $4.47 – $36.26
Volume: $5.03B
Avg Volume: $5.64B
Shares Outstanding: 87.3M
Next Earnings: Sep 16, 2026

Fundamentals Snapshot

Annual Revenue: $95M
Last Q Revenue: $24M
P/E Ratio: —
P/S Ratio: —
EPS (TTM): $-2.03
Dividend Yield: —

Why Investors Own OLMA

✓High-growth profile — revenue up +11.3% YoY with expanding US Equity exposure.
✓Healthy economics — 56% gross margin and 19% free-cash-flow margin.
✓New products and segments could unlock additional revenue streams.

⚠️ Key Risks

Execution delays, intensifying competition, and valuation compression if growth decelerates.

Financial Trends

Revenue (TTM)

$95M▲ +10.7% YoY

Gross Margin (TTM)

55.6%▲ +1.4% YoY

Operating Income (TTM)

$27M▲ +10.7% YoY

Free Cash Flow (TTM)

$18M▲ +10.7% YoY

About OLEMA PHARMACEUTICALS INC

Olema Pharmaceuticals, Inc., a biopharmaceutical enterprise in the clinical development stage, is dedicated to discovering, advancing, and commercializing therapeutic solutions for women's oncology. Headquartered in San Francisco, California, the company was established in 2006 and rebranded from CombiThera, Inc. in March 2009. Its most promising investigational compound, OP-1250, an estrogen receptor (ER) antagonist and selective ER degrader, is presently undergoing Phase 1/2 clinical evaluations. This drug candidate is being assessed for its efficacy in managing recurrent, locally advanced, or metastatic breast cancer that expresses estrogen receptors but is negative for human epidermal growth factor receptor 2.

🦦